Alpha Cognition Reports Q4 2025 Financial Results and Operational Update: Strong ZUNVEYL Commercial Performance and Payer Progress

Alpha Cognition reported FY25 financial results and provided an operational update. The company generated approximately $2.5 million in net product revenue in Q4, with launch-to-date net product revenue at $6.8 million. ZUNVEYL commercial performance showed a 62% QoQ growth in bottles dispensed and a 50% increase in prescribers. The company executed a second national PBM contract and plans to initiate the CONVERGE study in the long-term care environment.